Bioneer Q1 2026 Consolidated Operating Loss, but Subsidiary AceBiome Strong

Consolidated revenue: 81.8bn KRW (+10.7% YoY), operating loss 0.5bn KRW (vs. operating profit 4.3bn KRW in Q1 2025)
Probiotics segment (subsidiary AceBiome): revenue 76.2bn KRW, operating profit 7.2bn KRW, continues as cash cow
Molecular diagnostics segment: revenue 9.6bn KRW, operating loss 6.5bn KRW (R&D burden for next-gen platforms ExiStation FA and IRON-qPCR)
RNAi drug development: revenue 0.16bn KRW, operating loss 2.1bn KRW (SRN-001 Phase 1b IND approved, subject recruitment started Dec 2025)
Consolidated net loss: 2.8bn KRW (attributable to parent: 3.15bn KRW)
Standalone net profit: 12.7bn KRW (due to 20bn KRW dividend income from AceBiome)
Capital surplus transfer to cover deficits (~186.9bn KRW) turned retained earnings positive (standalone ~41.5bn KRW, consolidated ~129.4bn KRW)
No dividends or share buybacks
Debt ratio 69.1%, cash 54.4bn KRW (consolidated)
Major contingent liability: invention compensation lawsuit 5bn KRW (provision 1.2bn KRW)